Research Topics
Genomes and Genes | Gordon W DewaldSummaryAffiliation: Mayo Clinic Country: USA Publications
| Collaborators
|
Detail Information
Publications
FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophiliaAnimesh Pardanani
Division of Hematology and Internal Medicine, Laboratory Geentics and Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
Blood 104:3038-45. 2004..In contrast, only 40% partial response rate was seen in 10 HES cases. FIP1L1-PDGFRA is a relatively infrequent but treatment-relevant mutation in primary eosinophilia that is indicative of an underlying systemic mastocytosis...- Preclinical validation of fluorescence in situ hybridization assays for clinical practiceAnne E Wiktor
Division of Laboratory Genetics, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Genet Med 8:16-23. 2006..CONCLUSION: This report describes a method for preclinical validation of fluorescence in situ hybridization studies of metaphase cells and interphase nuclei using commercial or home brew probes... - Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemiaGordon W Dewald
Division of Laboratory Genetics, Mayo Clinic, Rochester, MN 55905, USA
Br J Haematol 121:287-95. 2003..Importantly, only CD38+ was significantly associated with high-risk FISH categories (+12, 11q- and 17p-) after adjustment for the effects of other variables... 
Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myelomaGordon W Dewald
Cytogenetics Laboratory, Mayo Clinic, Rochester, MN 55905, USA
Blood 106:3553-8. 2005....- Fluorescence in situ hybridization to visualize genetic abnormalities in interphase cells of acinar cell carcinoma, ductal adenocarcinoma, and islet cell carcinoma of the pancreasGordon W Dewald
Division of Laboratory Genetics, Mayo Clinic, Rochester, MN 55905, USA
Mayo Clin Proc 84:801-10. 2009..To use fluorescence in situ hybridization (FISH) to visualize genetic abnormalities in interphase cell nuclei (interphase FISH) of acinar cell carcinoma, ductal adenocarcinoma, and islet cell carcinoma of the pancreas... 
Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: clinicopathologic correlations and new insights from the pre-lenalidomide eraShernan G Holtan
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
Am J Hematol 83:708-13. 2008..Additional important prognostic factors not taken into account by the IPSS include the baseline erythrocyte indices, lymphocyte count, and clonal burden...- Fluorescent-labeled DNA probes applied to novel biological aspects of B-cell chronic lymphocytic leukemiaStephanie R Fink
Division of Laboratory Genetics, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Leuk Res 29:253-62. 2005..Deletions in IGHv occurred in 25% of patients and correlated with IGHv gene expression. Probes for 6q23 detected more deletions in 6q than probes for 6q21... - Primary myelofibrosis is the most frequent myeloproliferative neoplasm associated with del(5q): clinicopathologic comparison of del(5q)-positive and -negative casesRafael Santana-Davila
Division of Hematology, Mayo Clinic, Rochester, MN, USA
Leuk Res 32:1927-30. 2008..When used, lenalidomide therapy induced hematological and cytogenetic remissions in del(5q)-positive PMF. The current study identifies PMF as another del(5q)-associated myeloid malignancy with characteristic megakaryocyte morphology... - Clinical and biologic implications of recurrent genomic aberrations in myelomaRafael Fonseca
Mayo Cinic Division of Hematology, Department of Laboratory Medicine, Rochester, MN 55905, USA
Blood 101:4569-75. 2003..More importantly it provides further compelling evidence that MM is composed of subgroups of patients categorized according to their underlying genomic aberrations... - Loss of TP53 is due to rearrangements involving chromosome region 17p10 approximately p12 in chronic lymphocytic leukemiaStephanie R Fink
Cytogenetics Laboratory, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Cancer Genet Cytogenet 167:177-81. 2006..Translocations or isochromosome formations at sites of low-copy DNA repeats in 17p10 to 17p12 appear to be the mechanism for the loss of TP53 in B-CLL... - The incidence and anatomic site specificity of chromosomal translocations in primary extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) in North AmericaEllen D Remstein
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester MN 55905, USA
Am J Surg Pathol 30:1546-53. 2006..Differences in incidence and anatomic site specificity of translocations between North American and non-North American cases may reflect geographic variability of infectious or other etiologic factors... - Chromosome 5q deletion: specific diagnoses and cytogenetic details among 358 consecutive cases from a single institutionRafael Santana-Davila
Division of Hematology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
Leuk Res 32:407-11. 2008..We conclude that del(5q), although most prevalent in MDS, is seen across the spectrum of myeloid disorders including MPD and its occurrence in lymphoid disorders might signify, for the most part, an occult myeloid clone... - Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemiaNeil E Kay
Mayo Clinic, Stabile 628, 200 First St SW, Rochester, MN 55905, and The Ohio State University, Columbus, USA
Blood 109:405-11. 2007.... - Metaphase cells with normal G-bands have cryptic interstitial deletions in 13q14 detectable by fluorescence in situ hybridization in B-cell chronic lymphocytic leukemiaKimberly J Stockero
Cytogenetics Laboratory, Mayo Clinic, Rochester, MN 55905, USA
Cancer Genet Cytogenet 166:152-6. 2006..As a result of this study, we report evidence that B-CLL metaphases with 13q- are not detected because these deletions are often cryptic and not visible by standard G-banding... - Percentage of smudge cells on routine blood smear predicts survival in chronic lymphocytic leukemiaGrzegorz S Nowakowski
Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
J Clin Oncol 27:1844-9. 2009..In this study, we evaluated whether the smudge cell percentage on a blood smear predicted survival of CLL patients... - Frequency, hematopathology, and detection of a new isodicentric variant of deletion 20qStephanie A Smoley
Division of Laboratory Genetics, Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Cancer Genet Cytogenet 173:144-9. 2007..This study shows ider(20q) is common in clinical practice--1/10th the incidence of del(20q)--and is strongly associated with myelodysplasia and acute myeloid leukemia... - Immunoglobulin diversity gene usage predicts unfavorable outcome in a subset of chronic lymphocytic leukemia patientsRenee C Tschumper
Department of Immunology, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
J Clin Invest 118:306-15. 2008..In addition, these data support the concept that antigen-driven selection of specific Ig receptors plays a role in the clinical course of B-CLL... - Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology GroupMark R Litzow
Mayo Clinic, Rochester, MN 55905, USA
Br J Haematol 148:217-25. 2010..We conclude that none of these three regimens were effective enough in the treatment of high-risk relapsed or refractory AML to warrant further study. This trial was registered at http://www.clinicaltrials.gov as #NCT00005962... - Efficacy of conventional cytogenetics and FISH for EGR1 to detect deletion 5q in hematological disorders and to assess response to treatment with LenalidomideYing S Zou
Cytogenetics and Hematology, Mayo Clinic, Rochester, MN 55905, USA
Leuk Res 31:1185-9. 2007..FISH did not detect anomalies other than deletion 5q in 31 patients. This study suggests FISH is useful to detect deletion 5q, but is not a substitute for conventional cytogenetics... - Prognostic diversity among cytogenetic abnormalities in myelofibrosis with myeloid metaplasiaAyalew Tefferi
Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
Cancer 104:1656-60. 2005..The current prospective study addresses this issue in the context of currently accepted independent prognostic variables... - Genomic abnormalities in monoclonal gammopathy of undetermined significanceRafael Fonseca
Division of Hematology and Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
Blood 100:1417-24. 2002..Similar translocations are found in both MGUS and MM, including t(4;14)(p16.3;q32) and t(14;16)(q32;q23). Moreover, Delta 13 is common in MGUS and unlikely to play a predominant role in the evolution of MGUS to MM... - Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemiaTait D Shanafelt
Mayo Clinic College of Medicine, Department of Internal Medicine, Division of Hematology, Rochester, MN 55905, USA
J Clin Oncol 24:4634-41. 2006..These findings have important implications for both clinical management and trials of early treatment for patients with high-risk, early-stage CLL... - The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myelomaRafael Fonseca
Mayo Clinic Division of Hematology, The Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
Blood 102:2562-7. 2003..The classification of MM into hyperdiploidy and nonhyperdiploidy is dictated largely by the recurrent (primary) IgH translocations in the latter... - Clonal cytogenetic abnormalities in bone marrow specimens without clear morphologic evidence of dysplasia: a form fruste of myelodysplasia?David P Steensma
Department of Internal Medicine, Division of Hematology, Mayo Clinic Rochester, 200 First Street SW, Rochester, MN 55905, USA
Leuk Res 27:235-42. 2003..Continued follow-up of this heterogeneous cohort and further studies of similar patients will more clearly define the disease processes and prognosis for this constellation of laboratory findings... - Both B and T lymphocytes may be clonally involved in myelofibrosis with myeloid metaplasiaTerra L Reeder
Mayo Clinic, Rochester, MN 55905, USA
Blood 101:1981-3. 2003..The current study provides direct evidence for the clonal involvement of both B and T lymphocytes in MMM. A larger study is needed to clarify the relevance of the observed interpatient heterogeneity in clonal constitution... - Chronic myeloid leukemia: current application of cytogenetics and molecular testing for diagnosis and treatmentAyalew Tefferi
Department of Internal Medicine and Division of Hematology, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
Mayo Clin Proc 80:390-402. 2005..These issues are discussed within the context of clinical practice... - CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potentialTait D Shanafelt
Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Br J Haematol 140:537-46. 2008..Importantly, anti-CD49d antibodies are already approved for treatment of other human diseases. Clinical testing of anti-CD49d therapy in CLL appears warranted... - Respective clustering of unfavorable and favorable cytogenetic clones in myelofibrosis with myeloid metaplasia with homozygosity for JAK2(V617F) and response to erythropoietin therapyAyalew Tefferi
Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
Cancer 106:1739-43. 2006..For the current study, the authors explored the relation between specific cytogenetic clones and JAK2(V617F) mutational status in patients with MMM and the effects on treatment response to erythropoietin (Epo)... - Philadelphia chromosome mosaicism at diagnosis in chronic myeloid leukemia: clinical correlates and effect on imatinib mesylate treatment outcomeAndrew P Landstrom
Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
Leuk Lymphoma 48:2137-40. 2007..Multivariable analysis identified Ph mosaicism as a risk factor for shortened survival. Due to the small sample size, the current preliminary observations require validation in a larger group of patients... - Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patientsRafael Fonseca
Mayo Clinic Department of Hematology and Internal Medicine, Minneapolis, MN 55905, USA
Blood 99:3735-41. 2002..These patients do not have a worsened prognosis as previously thought... - Clinical correlates of submicroscopic deletions involving the ABL-BCR translocation region in chronic myeloid leukemiaYinlee Yoong
Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
Eur J Haematol 74:124-7. 2005..These results are contrary to previous reports that suggested inferior survival as well as poor response to alpha interferon therapy in CML patients carrying der(9) deletions... - Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosisDavid Dingli
Division of Hematology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
Cancer 106:1985-9. 2006..CONCLUSIONS: The results of the current study suggest that cytogenetic findings might supersede AMM-derived prognostic scoring systems for predicting survival in patients with sMF... - Adult B-cell lymphomas with burkitt-like morphology are phenotypically and genotypically heterogeneous with aggressive clinical behaviorRebecca F McClure
Department of Laboratory Medicine and Pathology, Divisions of Anatomic Pathology and Hematopathology, Mayo Clinic, Rochester, MN 55905, USA
Am J Surg Pathol 29:1652-60. 2005.... - Mucosa-associated lymphoid tissue lymphomas with t(11;18)(q21;q21) and mucosa-associated lymphoid tissue lymphomas with aneuploidy develop along different pathogenetic pathwaysEllen D Remstein
Division of Anatomic Pathology and Hematopathology, Mayo Clinic, Rochester, Minnesota 55905, USA
Am J Pathol 161:63-71. 2002..Both t(11;18) and aneuploidy were seen disproportionately in lung, and both were associated with recurrent disease... - Standardization of fluorescence in situ hybridization studies on chronic lymphocytic leukemia (CLL) blood and marrow cells by the CLL Research ConsortiumStephanie A Smoley
Cytogenetics, Division of Laboratory Genetics, Department of Laboratory Medicine, 200 First Street SW, Rochester, MN 55905, USA
Cancer Genet Cytogenet 203:141-8. 2010..Individual laboratories can help by closely following rigorous quality assurance guidelines to ensure accurate and consistent FISH studies in their clinical practice and research... - Cytogenetic and FISH studies in myelodysplasia, acute myeloid leukemia, chronic lymphocytic leukemia and lymphomaGordon W Dewald
Division of Laboratory Genetics, Mayo Clinic, Rochester, MN, USA
Int J Hematol 76:65-74. 2002..New methods to extract individual nuclei from paraffin-embedded tissue are now available which permit the use of interphase FISH to detect important chromosome anomalies in lymphoma... - Cytogenetics of chronic myeloproliferative disorders and related myelodysplastic syndromesAdewale Adeyinka
Department of Laboratory Medicine and Pathology, Division of Laboratory Genetics, Mayo Clinic Rochester, 200 First Street Southwest, Rochester MN 55905, USA
Hematol Oncol Clin North Am 17:1129-49. 2003..FISH techniques are useful for MPD to study inadequate bone marrow or blood specimens and to monitor disease status among patients with known chromosome anomalies, but they are not more sensitive than conventional chromosome studies... - New highly sensitive fluorescence in situ hybridization method to detect PML/RARA fusion in acute promyelocytic leukemiaStephanie R Brockman
Division of Laboratory Genetics, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Cancer Genet Cytogenet 145:144-51. 2003..In addition, this FISH method can detect all alternate translocations involving RARA and not PML. This FISH method can be used both for the accurate diagnosis of APL and to monitor low levels of disease in treated patients... - A novel tricolor, dual-fusion fluorescence in situ hybridization method to detect BCR/ABL fusion in cells with t(9;22)(q34;q11.2) associated with deletion of DNA on the derivative chromosome 9 in chronic myelocytic leukemiaStephanie A Smoley
Division of Laboratory Genetics, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Cancer Genet Cytogenet 148:1-6. 2004.... - CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapyAnimesh Pardanani
Division of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Blood 102:3093-6. 2003..Screening for the FIP1L1-PDGFRA rearrangement and Asp816Val mutation will advance rational therapy decisions in SMCD... - A new method to extract nuclei from paraffin-embedded tissue to study lymphomas using interphase fluorescence in situ hybridizationSarah F Paternoster
Division of Laboratory Genetics, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
Am J Pathol 160:1967-72. 2002..This FISH technique is useful to detect chromosome anomalies with high sensitivity and specificity in paraffin-embedded tissue and may provide important diagnostic and prognostic genetic information... - Molecular cytogenetic studies for hematological malignanciesGordon W Dewald
Cytogenetics Laboratory, Mayo Clinic, Rochester, MN, USA
Cancer Treat Res 121:69-112. 2004 - Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an eastern cooperative oncology group studyRafael Fonseca
Department of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
Cancer Res 62:715-20. 2002..03). The presence of Delta13 is an important and independent adverse prognostic factor in newly diagnosed MM and is associated with specific biological features... - Primary myelodysplastic syndrome with normal cytogenetics: utility of 'FISH panel testing' and M-FISHRhett P Ketterling
Department of Laboratory Medicine and Pathology, Mayo Clinic/Foundation, 200 First Street S.W, Rochester, MN 55905, USA
Leuk Res 26:235-40. 2002..These findings confirm standard cytogenetics as an excellent technique in identifying the common chromosomal abnormalities associated with MDS and suggest limited utility for either a FISH panel test or M-FISH in primary MDS... - The prognostic significance of trisomy 8 in patients with acute myeloid leukemiaMichelle A Elliott
Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
Leuk Lymphoma 43:583-6. 2002..The presence of +8 did not appear to adversely affect the outcome of patients with favorable karyotypes... - Prevalence, breakpoint distribution, and clinical correlates of t(5;12)Patricia T Greipp
Division of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Cancer Genet Cytogenet 153:170-2. 2004..1) and ACMD,t(5;12)(q31;q24.1)]. The t(5;12) is a rare, myelocytic-exclusive cytogenetic abnormality with a breakpoint-specific association with eosinophilia or monocytosis... - Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasiaAyalew Tefferi
Mayo Clinic, Rochester, MN 55905, USA
Blood 99:3854-6. 2002..In vitro, imatinib mesylate caused variable degrees of growth suppression of myeloid and erythroid progenitors that unfortunately did not translate into clinical benefit... - Hematologic malignancies, critical genes and representative pictures for 166 chromosome anomaliesVictor J Mahaffey
Division of Laboratory Genetics, Cytogenetics Laboratory, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Leuk Res 28:1351-6. 2004 - Interphase FISH studies of chronic myeloid leukemiaGordon W Dewald
Laboratory Medicine and Medical Genetics, Mayo Clinic, Rochester, MN, USA
Methods Mol Biol 204:311-42. 2002 - Primer on medical genomics part II: Background principles and methods in molecular geneticsAyalew Tefferi
Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
Mayo Clin Proc 77:785-808. 2002.... - A phase II trial of arsenic trioxide for relapsed and refractory acute lymphoblastic leukemiaMark R Litzow
Division of Hematology, Mayo Clinic College of Medicine, 200 First St S W, Rochester, MN 55905, USA
Haematologica 91:1105-8. 2006..One patient died of an infection. There were no responses. Ten patients have died. The median survival was 3.2 months (range 1.2-4.1). We conclude that AT is not active in the treatment of ALL... - Primer on medical genomics. Part XI: Visualizing human chromosomesJack L Spurbeck
Cytogenetics Laboratory, Division of Laboratory Genetics, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
Mayo Clin Proc 79:58-75. 2004..The clinical diagnosis, prognosis, and response to treatment can be established for many malignant diseases. Cytogenetic methods provide an important diagnostic tool for clinical practice... - Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5qAzra Raza
Rush University Medical Center, Chicago, IL, USA
Blood 111:86-93. 2008..Lenalidomide has clinically meaningful activity in transfusion-dependent patients with low- or int-1-risk MDS who lack the deletion 5q karyotypic abnormality... - Comparison of interphase FISH and metaphase cytogenetics to study myelodysplastic syndrome: an Eastern Cooperative Oncology Group (ECOG) studyAthena M Cherry
Department of Pathology, Stanford Hospital and Clinics, Stanford, CA 94305, USA
Leuk Res 27:1085-90. 2003..In addition, it appears that interphase FISH studies are nearly as sensitive as cytogenetic analyses and can be a useful tool in studying bone marrow aspirates where cytogenetic analysis is not possible... - Peripheral blood cytogenetic studies in myelofibrosis: overall yield and comparison with bone marrow cytogenetic studiesKebede Hussein
Division of Hematology, Rochester, MN, United States
Leuk Res 32:1597-600. 2008..These results suggest that PB can be considered as an alternative to BM for cytogenetic studies as currently used in MF but additional prospective studies are needed to support change in practice... - Correlation of three methods of measuring cytogenetic response in chronic myelocytic leukemiaMartin L Lesser
North Shore Long Island Jewish Research Institute, Manhasset, NY, USA
Cancer Genet Cytogenet 137:79-84. 2002..The results indicate that mixing data of different methods to measure treatment response within or between patients may be misleading clinical index... - Karyotype evolution on fluorescent in situ hybridization analysis is associated with short survival in patients with chronic lymphocytic leukemia and is related to CD49d expressionTait D Shanafelt
J Clin Oncol 26:e5-6. 2008 - Cytogenetic abnormalities can change during the course of the disease process in chronic lymphocytic leukemiaTait D Shanafelt
J Clin Oncol 24:3218-9; author reply 3219-20. 2006 - Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemiaRebekah L Browning
Ohio State University, Columbus, OH, United States
Leuk Res 31:1737-40. 2007..199) were noted with lower TCL-1 expression. These data suggest TCL-1 expression may help predict treatment outcome in CLL patients following chemoimmunotherapy, and examination in larger studies is warranted... - Chronic lymphocytic leukemia FISH panel: impact on diagnosisBeverly P Nelson
Department of Pathology, Feinberg Medical School, Northwestern University, Chicago, IL 60611 2908, USA
Am J Clin Pathol 128:323-32. 2007..Morphologic features were atypical for CLL in 2 cases with IGH fusion (BCL11A and BCL3). The FISH CLL panel is useful to identify prognostic aberrations and to clarify diagnosis in cases with unusual morphologic features... - The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocationsFrederick R Appelbaum
Southwest Oncology Group Statistical Center, Seattle, WA, USA
Br J Haematol 135:165-73. 2006..021), and in patients with t(8;21) (P = 0.025). OS was superior in patients who received regimens with high-dose cytarabine, a combination of fludarabine and intermediate-dose cytarabine, or haematopoietic cell transplantation... - Utility of interphase FISH to stratify patients into cytogenetic risk categories at diagnosis of AML in an Eastern Cooperative Oncology Group (ECOG) clinical trial (E1900)Gail H Vance
Medical and Molecular Genetics, Indiana University School of Medicine, 975 W Walnut Street IB 264, Indianapolis, IN 46202, USA
Leuk Res 31:605-9. 2007.... - Der(6)t(1;6)(q21-23;p21.3): a specific cytogenetic abnormality in myelofibrosis with myeloid metaplasiaDavid Dingli
Division of Hematology and Department of Internal Medicine, Mayo Clinic Rochester, MN, USA
Br J Haematol 130:229-32. 2005..In a preliminary fluorescence in situ hybridization study, the breakpoints on chromosome 6 in two additional cases were found to be telomeric to the gene for 51 kDa FK506-binding protein (FKBP51)... - Delineation of the minimal commonly deleted segment and identification of candidate tumor-suppressor genes in del(9q) acute myeloid leukemiaDavid A Sweetser
Department of Pediatrics, Massachusetts General Hospital, 55 Fruit Street Jackson 904, Boston, MA 02114, USA
Genes Chromosomes Cancer 44:279-91. 2005..The results of our studies are consistent with a model of tumor suppression mediated by haploinsufficiency of critical genes in del(9q) AML... - The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromesDavid P Steensma
Mayo Clinic and Mayo Clinic College of Medicine, Rochester MN 55905, USA
Blood 106:1207-9. 2005..The current observation strengthens the specific association between JAK2 V617F and classic MPD, but also suggests an infrequent occurrence in other myeloid disorders... - Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trialAnthony V Moorman
Leukaemia Research Cytogenetics Group, Cancer Sciences Division, University of Southampton, Southampton General Hospital, Southampton, UK
Blood 109:3189-97. 2007.... - Proficiency testing for laboratories performing fluorescence in situ hybridization with chromosome-specific DNA probesJames T Mascarello
Genetic Services, Children s Hospital, San Diego, Calif 92123, USA
Arch Pathol Lab Med 126:1458-62. 2002..The extraordinary variation in ISCN descriptions submitted by participants showed that the existing system for human cytogenetic nomenclature is not suitable for facile communication of FISH test results... - Intensified induction chemotherapy in adult acute myeloid leukemia followed by high-dose chemotherapy and autologous peripheral blood stem cell transplantation: an Eastern Cooperative Oncology Group trial (E4995)Peter A Cassileth
University of Miami Sylvester Comprehensive Cancer Center, Miami, FL 33136, USA
Leuk Lymphoma 46:55-61. 2005..Nevertheless, intensive post-remission therapy was well tolerated, no treatment-related mortality occurred with autologous PBSCT, and disease-free survival and overall survival were lengthy... - Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remissionMartin S Tallman
Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
Blood 110:409-17. 2007..However, treatment-related mortality was high. Matched unrelated donor HSCT should be considered for all patients with unfavorable cytogenetics who lack a suitable HLA-matched sibling donor... - Problems with ISCN FISH Nomenclature make it not practical for use in clinical test reports or cytogenetic databases [corrected]James T Mascarello
Genzyme Genetics, Santa Fe, New Mexico 87505, USA
Genet Med 5:370-7. 2003..Because methodological information contributes a large amount of variability, adds complexity, and increases opportunities for syntax errors, a system that excludes such information would be more effective... - Guidance for fluorescence in situ hybridization testing in hematologic disordersDaynna J Wolff
Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, South Carolina, USA
J Mol Diagn 9:134-43. 2007.... - Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997Ian W Flinn
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD, USA
J Clin Oncol 25:793-8. 2007..E2997 is a phase III randomized Intergroup trial comparing fludarabine and cyclophosphamide (FC arm) versus fludarabine (F arm) alone in patients receiving their first chemotherapy regimen for CLL...